Previous studies have shown that ILA in cancer patients increases the risk of developing severe pneumonitis as a side effect of systemic chemotherapy, radiation therapy and immune checkpoint inhibitors [25, 32–34]. Here, TNFRSF9 is linked to pneumonitis.